secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2024-07-23T23:59:59+00:00
Accession:  0001104659-24-081717
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M
--------------------------------------------------------------------------------

- ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.
- Total revenue $108.6M (Q2 2024) vs $71.5M (Q2 2023); net loss $3.9M vs net income $15.0M YoY.
- 2024 ARCALYST net revenue guidance increased to $405-415M from prior $370-390M.
- Cash and investments $218.8M, no debt; expects to remain cash flow positive annually.
- Phase 2b trial of abiprubart in Sjögren's Disease enrolling; clinical development fully funded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924081717/0001104659-24-081717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465924081717/tm2419915d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-081717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer